150 related articles for article (PubMed ID: 28731370)
1. An Evaluation of a Factor Xa-Based Clotting Time Test for Enoxaparin: A Proof-of-Concept Study.
Ng DPJ; Duffull SB; Faed JM; Isbister GK; Gulati A
Clin Appl Thromb Hemost; 2018 May; 24(4):669-676. PubMed ID: 28731370
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2012 Jan; 29(1):225-35. PubMed ID: 21822767
[TBL] [Abstract][Full Text] [Related]
3. Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2015 Oct; 32(10):3391-402. PubMed ID: 26129765
[TBL] [Abstract][Full Text] [Related]
4. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF; Martin EJ; Gehr TW; Carr ME
Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
[TBL] [Abstract][Full Text] [Related]
7. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
Yildirim T; Kocak T; Buyukasik Y; Yilmaz R; Altun B; Erdem Y; Arici M
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):700-4. PubMed ID: 23135378
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
10. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
Schaden E; Schober A; Hacker S; Spiss C; Chiari A; Kozek-Langenecker S
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
12. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
13. In vitro anticoagulation monitoring of low-molecular-weight heparin.
Wang JQ; Shi XB; Yang JG; Hu DY
Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
[TBL] [Abstract][Full Text] [Related]
14. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
[TBL] [Abstract][Full Text] [Related]
15. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
16. Does prior administration of enoxaparin influence the effects of levobupivacaine on blood clotting? Assessment using the Thrombelastograph.
Leonard SA; Lydon A; Walsh M; Fleming C; Boylan J; Shorten GD
Br J Anaesth; 2001 Jun; 86(6):808-13. PubMed ID: 11573588
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
[TBL] [Abstract][Full Text] [Related]
18. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
[TBL] [Abstract][Full Text] [Related]
20. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
